GABAA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis

Neurology. 2020 Sep 1;95(9):399-401. doi: 10.1212/WNL.0000000000010310. Epub 2020 Jul 10.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Alemtuzumab / adverse effects*
  • Autoantibodies / immunology*
  • Autoimmune Diseases of the Nervous System / chemically induced*
  • Autoimmune Diseases of the Nervous System / immunology
  • Autoimmune Diseases of the Nervous System / physiopathology
  • Autoimmune Diseases of the Nervous System / therapy
  • Autoimmunity / immunology
  • B-Lymphocytes
  • Electroencephalography
  • Encephalitis / chemically induced*
  • Encephalitis / immunology
  • Encephalitis / physiopathology
  • Encephalitis / therapy
  • Epilepsia Partialis Continua / chemically induced
  • Epilepsia Partialis Continua / immunology
  • Epilepsia Partialis Continua / physiopathology
  • Epilepsia Partialis Continua / therapy
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • Lymphocyte Activation
  • Magnetic Resonance Imaging
  • Male
  • Methylprednisolone / therapeutic use
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Receptors, GABA-A / immunology*
  • Seizures / chemically induced*
  • Seizures / immunology
  • Seizures / physiopathology
  • Seizures / therapy
  • Status Epilepticus / chemically induced
  • Status Epilepticus / immunology
  • Status Epilepticus / physiopathology
  • Status Epilepticus / therapy
  • T-Lymphocytes

Substances

  • Autoantibodies
  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Receptors, GABA-A
  • Alemtuzumab
  • Methylprednisolone